Immunotherapy Takes Hold in Frontline Advanced Nonsquamous NSCLC
November 18th 2019Jyoti D. Patel, MD, FASCO, discusses the implications of genetic testing, the lasting impact of the KEYNOTE and IMpower trials in patients with advanced nonsquamous non–small cell lung cancer, and considerations for treatment selection.
Dr. Stadler on Active Surveillance in Prostate Cancer
August 1st 2019Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, dean for clinical research, director of the Genitourinary Oncology Program, and deputy director of the Comprehensive Cancer Center, at the University of Chicago Medicine, discusses the use of active surveillance in prostate cancer.
Dr. Stadler on the Therapeutic Landscape of RCC
April 11th 2019Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, chief of the Section of Hematology/Oncology, and director of the Genitourinary Program at the University of Chicago Medicine, discusses the therapeutic landscape of renal cell carcinoma (RCC).
Dr. Stadler on Approved and Investigational Therapies in RCC
October 2nd 2018Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, chief of the Section of Hematology/Oncology, and director of the Genitourinary Program at the University of Chicago Medicine, discusses approved and investigational therapies in renal cell carcinoma (RCC).
Dr. Stadler on Sequencing Therapies in Prostate Cancer
September 22nd 2018Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, chief of the Section of Hematology/Oncology, and director of the Genitourinary Program at the University of Chicago Medicine, discusses sequencing therapies in prostate cancer.